CorMedix Inc Company News

Old Arcived News About CorMedix Inc

• 1:41 pm Cormedix reports that the first patient has been enrolled and dosed in its LOCK-IT-100 Phase 3 clinical study of Neutrolin, to be used in preventing catheter-related bloodstream infections.
• CorMedix (CRMD) Stock Gains After Receiving Positive FDA Feedback for Neutrolin.
• Cormedix (CRMD): Today's Weak On High Volume Stock.
• CorMedix Announces Enrollment and Dosing of First Patient in Phase 3 Neutrolin® Trial in Hemodialysis. [PR Newswire] - BEDMINSTER, N.J., Dec. 14, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases, today announced that the first patient has been enrolled and dosed in the LOCK-IT-100 (Catheter Lock Solution Investigational Trial) Phase 3 clinical study. The LOCK-IT-100 study will assess the efficacy and safety of Neutrolin® in preventing catheter-related bloodstream infections (CRBSIs) in subjects receiving hemodialysis therapy as treatment for end stage renal disease to support marketing approval in the United States. "The start of our pivotal Phase 3 registration trial in the United States is a major milestone for CorMedix," said Randy Milby, Chief Executive Officer of CorMedix.
• CorMedix Inc. Abstracts Highlighting the Economic Burden of Central Venous Catheter Complications to be Presented at Kidney Week 2015. [Accesswire] - BEDMINSTER, NJ / ACCESSWIRE / October 5, 2015 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment ...
• CORMEDIX INC. FILES REQUEST WITH FDA FOR QIDP DESIGNATION FOR NEUTROLIN®. [at noodls] - BRIDGEWATER, N.J., December 4, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, ...
• CORMEDIX INC. Files SEC form 10-Q, Quarterly Report.
• CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers.
• CORMEDIX INC. Files SEC form 8-K, Other Events.
• CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits.
• CORMEDIX INC. Files SEC form 8-K, Termination of a Material Definitive Agreement.
• CorMedix Inc. Finalizes First Middle East Neutrolin® Sales/Distribution Agreement in the Kingdom of Saudi Arabia. [PR Newswire] - BRIDGEWATER, N.J., Dec. 23, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, announced today the first signed Middle East sales/distribution agreement for lead product Neutrolin with distributor Arabian Trade House in the Kingdom of Saudi Arabia. CorMedix's Neutrolin is a novel formulation of taurolidine, citrate and heparin with1000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis, and biofilm to keep catheter's operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation.
• CORMEDIX INC. Financials.
• CorMedix Inc. to Present at Dawson James Securities Growth Stock Conference. [Accesswire] - BEDMINSTER, NJ / ACCESSWIRE / September 24, 2015 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment ...
• CorMedix Inc. to Present at Salomon Bio Investment and Leadership Conference. [Accesswire] - BEDMINSTER, NJ / ACCESSWIRE / November 13, 2015 / CorMedix Inc. (NYSE MKT: CRMD) announced today that Randy Milby, CEO, will provide a company overview at the Salomon Bio Investment and Leadership Conference ...
• CorMedix, Inc. Earnings Q2, 2015.
• CorMedix, Inc. to Announce Third Quarter 2015 Results on November 12, 2015. [Accesswire] - Company to Host Conference Call at 9 am on Friday, November 13, 2015 BEDMINSTER, NJ / ACCESSWIRE / November 4, 2015 / CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a specialty pharmaceutical company ...
• FINAL NOTICE OF DEADLINE: Khang & Khang LLP Reminds Investors with Losses in CorMedix, Inc. of the September 4, 2015 Deadline. [Business Wire] - Khang & Khang LLP reminds investors in CorMedix, Inc. , who purchased or otherwise acquired shares between March 12, 2011 and July 29, 2015, inclusive , of the September 4, 2015, deadline to serve as lead plaintiff in the class action.
• How Is Smart Money Trading CorMedix Inc..
• Law Offices of Howard G. Smith Reminds Investors: Two Days Left To File Lead Plaintiff Motion In The Class Action Lawsuit Against CorMedix, Inc.. [Business Wire] - Law Offices of Howard G. Smith reminds investors of the September 4, 2015 lead plaintiff deadline in the class action lawsuit filed on behalf of a class comprising purchasers of the securities of CorMedix, Inc.
• NEUTROLIN LABEL EXPANSION APPROVED IN GERMANY. [at noodls] - BRIDGEWATER, N.J., December 3, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, ...
• Pacific Premier Bancorp, Inc. Announces the Appointment of New Director. [Business Wire] - Pacific Premier Bancorp, Inc. , the holding company of Pacific Premier Bank , announced today the expansion of its Board of Directors to eight members and the appointment of Cora Tellez as an independent director to fill the vacancy created as a result of such expansion.
• SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in CorMedix, Inc. To Contact the Firm Ahead of Imminent Lead Plaintiff Deadline. [Accesswire] - NEW YORK, NY / ACCESSWIRE / September 1, 2015 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CorMedix, Inc. ("CorMedix" or the "Company") (NYSE: ...
• SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of September 4, 2015. [Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP: